Targeting CLL1/TIM3 could be feasible not only in the CAR + CCR setting, but also in CAR + CAR approaches, thereby maximizing the number of targetable AML cells and minimizing chances of antigen escape. This evidence concerns the gene HAVCR2 and acute myeloid leukemia.